Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis Syndrome

Inclusion Criteria: * CNV of less than 1 year duration due to presumed ocular histoplasmosis * Ability to provide written informed consent and comply with study assessments for the full duration of the study * Age 21 years and older * Subfoveal or juxtafoveal CNV lesion of less than 5400um in diameter * Best corrected visual acuity of 20/25 to 20/400 * Birth control therapy for females of child-bearing age Exclusion Criteria: * CNV due to presumed ocular histoplasmosis for greater than 1 year * Pregnancy (positive pregnancy test) or lactation * Premenopausal women not using adequate contraception. The following are considered effective means of contraception : surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch * A recent history of smoking (within 1 year of study enrollment) * Prior treatment with intravitreal aflibercept injection * Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated * Uncontrolled glaucoma in the study eye (defined as IOP greater or equal to 30 mmHg despite treatment with anti-glaucoma medication) * History of cerebral vascular accident, myocardial infarction, transient ischemic attacks within 3 months of study enrollment * Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye * Presence of significant subfoveal fibrosis or atrophy * Intraocular surgery (including cataract surgery) in the study eye within 2 months of enrollment * Active intraocular inflammation (grade trace or above) in the study eye * History of allergy to fluorescein, ICG or iodine, not amendable to treatment * Any concurrent intraocular condition in the study eye (e.g., cataract or diabetic retinopathy) that, in the opinion of the investigator, could either * Require medical or surgical intervention during the 12 month study period to prevent or treat visual loss that might result from that condition, or * If allowed to progress untreated, could likely contribute to loss of at least 2 snellen equivalent lines of BCVA over the 12 month study period * Prior/Concomitant Treatment: * Panretinal photocoagulation treatment * Previous intraocular steroids or PDT within 3 months * Previous participation in any studies of investigational drugs within 30 days preceding Day 0 (excluding vitamins and minerals) * Previous treatment with intravitreally (in either eye) or intravenously administered Avastin (bevacizumab) within 60 days * Previous use of Macugen or Lucentis in study eye within 60 days * Prior submacular or vitreous surgery